While further research is warranted to elucidate the impact of uPA expression levels on treatment response, our study underscores the potential of targeting the uPA–uPAR system as a therapeutic strategy in pancreatic cancer management. The gene discussed is PLAU; the disease is pancreatic neoplasm.